Financial Performance - The company's operating revenue for Q3 2021 was ¥133,371,277.49, representing a year-on-year increase of 155.77%[5] - The net profit attributable to shareholders for Q3 2021 was ¥26,049,161.53, up 58.80% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥26,019,969.90, an increase of 89.29% year-on-year[5] - For the first three quarters of 2021, the total operating revenue reached ¥285,036,667.40, reflecting a growth of 60.35% compared to the same period last year[5] - The net profit attributable to shareholders for the first three quarters of 2021 was ¥77,811,695.98, which is a 31.79% increase year-on-year[5] - Operating profit for the first three quarters of 2021 was ¥91,338,382.34, compared to ¥75,545,868.75 in 2020, indicating an increase of about 20.9%[21] - Net profit attributable to shareholders of the parent company for the first three quarters of 2021 was ¥77,811,695.98, up from ¥59,040,696.18 in 2020, reflecting a growth of approximately 31.7%[22] Earnings Per Share - The basic earnings per share for Q3 2021 was ¥0.19, an increase of 18.75% compared to the previous quarter[6] - The diluted earnings per share for Q3 2021 was also ¥0.19, reflecting the same growth rate of 18.75%[6] - The basic earnings per share for the first three quarters of 2021 was ¥0.57, slightly down from ¥0.58 in the same period of 2020[22] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥1,071,861,212.13, representing a 7.47% increase from the end of the previous year[6] - The equity attributable to shareholders at the end of Q3 2021 was ¥861,718,472.81, which is a 5.97% increase compared to the end of the previous year[6] - Current assets totaled RMB 824,013,504.61, slightly up from RMB 822,220,361.70 year-over-year[16] - Non-current assets increased to RMB 247,847,707.52 from RMB 175,183,711.05, representing a growth of approximately 41.4%[17] - Total liabilities reached RMB 142,896,849.50, compared to RMB 119,788,274.83 in the previous year, indicating an increase of about 19.3%[17] - The total assets of the company amounted to ¥1,071,861,212.13, an increase from ¥997,404,072.75 in the previous year, indicating a growth of about 7.4%[18] - The company's total equity reached ¥928,964,362.63, up from ¥877,615,797.92, reflecting an increase of approximately 5.8%[18] Cash Flow - The company reported a net cash flow from operating activities of ¥21,149,578.87 for the first three quarters of 2021, compared to ¥18,138,567.14 in the same period of 2020, showing an increase of about 11.1%[24] - The net cash flow from investing activities was -$182.35 million, compared to -$43.44 million in the previous period[25] - The total cash outflow from investing activities amounted to $302.74 million, with $250 million specifically for investment payments[25] - The net cash flow from financing activities was -$35.63 million, with cash inflow from borrowings at $33.72 million[25] - The company distributed dividends and interest payments totaling $27.82 million[25] - The net increase in cash and cash equivalents was -$197.03 million, contrasting with an increase of $8.49 million in the previous period[25] - The ending balance of cash and cash equivalents stood at $362.85 million, down from $559.88 million at the beginning of the period[25] Research and Development - Research and development expenses for the first three quarters of 2021 totaled ¥16,082,970.74, compared to ¥10,283,807.81 in 2020, marking a rise of approximately 56.5%[21] Other Information - The company has not reported any new product launches or technological advancements during this quarter[14] - There are no significant mergers or acquisitions reported in the current quarter[14] - The company did not apply the new leasing standards starting from 2021[25]

Financial Performance - The company achieved operating revenue of CNY 151,665,389.91, representing a 20.74% increase compared to the same period last year[19]. - The net profit attributable to shareholders reached CNY 51,762,534.45, up 21.40% year-on-year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 46,411,777.07, reflecting a 24.62% increase from the previous year[19]. - The net cash flow from operating activities was CNY 27,478,194.54, a decrease of 3.83% compared to the same period last year[19]. - The company's net assets attributable to shareholders increased to CNY 864,909,311.28, a growth of 6.37% from the end of the previous year[19]. - Total assets reached CNY 1,037,013,220.92, marking a 3.97% increase compared to the end of the previous year[19]. - Basic earnings per share decreased to CNY 0.38, down 9.52% from the same period last year[20]. - The weighted average return on net assets was 6.17%, a decrease of 7.75 percentage points year-on-year[20]. - The growth in performance for the first half of 2021 was primarily driven by an increase in operating profit[20]. - The total comprehensive income for the first half of 2021 was CNY 56,231,259.81, compared to CNY 46,473,321.24 in the previous year, reflecting a growth of approximately 20.00%[157]. Industry Position and Market Trends - The company operates in the specialized equipment manufacturing industry, specifically in the sub-sector of other specialized equipment manufacturing[26]. - The intelligent pharmaceutical management equipment manufacturing industry has seen rapid development since the early 2000s, with automation technology being increasingly adopted in hospitals[27]. - The company is positioned to benefit from the increasing demand for intelligent pharmaceutical management systems due to rising drug varieties and quantities in hospitals[29]. - The establishment of intravenous medication preparation centers has created broader development space for intelligent pharmaceutical management[30]. - The Chinese government has implemented policies to enhance the automation and efficiency of pharmaceutical management in hospitals, promoting the adoption of high-tech automated equipment[31]. - The company is expected to leverage the growth in the retail pharmacy sector driven by "Internet + healthcare" policies, which will encourage the transformation and upgrading of retail pharmacies[32]. - The "14th Five-Year Plan" emphasizes the construction of a high-quality and efficient healthcare service system, which aligns with the company's strategic goals[32]. - The company has a market share of 30.20% in the outpatient pharmacy automation sector, ranking first in the industry as of the end of 2018[34]. Research and Development - R&D expenses increased to 9.82 million yuan, reflecting a growth of 57.94% year-on-year, driven by enhanced investment in new product development[52]. - The company has established a comprehensive R&D system and has a team with nearly 20 years of experience in intelligent drug management[45]. - The company is currently developing new products such as hospital logistics robots, automated pharmacies, and automated traditional Chinese medicine dispensing machines[38]. - The company's intelligent pharmacy project enhances drug dispensing efficiency and reduces human error through automated systems[36]. - The intelligent intravenous preparation center project allows for rapid and accurate preparation of intravenous medications, minimizing direct contact with toxic chemicals[37]. Financial Management and Cash Flow - Cash and cash equivalents at the end of the period decreased by 25.56% to ¥416.80 million, accounting for 40.20% of total assets, primarily due to the purchase of financial products[64]. - Trading financial assets increased to ¥100.00 million, representing 9.64% of total assets, mainly from the purchase of wealth management products[64]. - Accounts receivable rose by 6.85% to ¥221.38 million, accounting for 21.35% of total assets, driven by increased sales[64]. - Inventory increased by 59.00% to ¥39.15 million, representing 3.78% of total assets, as a result of increased stocking due to higher sales[64]. - The company reported a net cash flow from investment activities of -162,608,247.43 RMB, a significant increase in outflow compared to -29,931,593.56 RMB last year[163]. - The total cash and cash equivalents at the end of the period were 416,801,959.98 RMB, down from 559,879,717.59 RMB at the beginning of the period[163]. Shareholder Commitments and Governance - The company has committed to a share lock-up period from December 22, 2020, to December 21, 2023, for major shareholders and actual controllers[94]. - The company has ensured compliance with all commitments made during the reporting period, with no delays or failures reported[95]. - The company has outlined a strategy to address competition and related party transactions, ensuring long-term stability[97]. - The company commits to not transferring or entrusting the management of shares held before the issuance for 36 months post-IPO[100]. - The company will publicly apologize and disclose reasons for any failure to meet commitments in designated media[14]. - The company emphasizes compliance with all relevant laws and regulations regarding shareholding changes[101]. Related Party Transactions and Legal Compliance - The company reported a related party transaction with Willach amounting to 13,516,758.60 RMB, which represents 51.99% of the estimated transaction amount of 26 million RMB for 2021[129]. - The company confirmed that there are no undisclosed related party transactions that should be reported according to legal regulations[126]. - The controlling shareholders and actual controllers have committed to avoid any competitive business activities with the company[124]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[127]. - The company has not received any penalties or corrective actions related to violations of laws or regulations during the reporting period[128]. Future Outlook and Strategic Initiatives - The company plans to continue expanding its capital base to support future growth initiatives[171]. - The increase in unallocated profits suggests a focus on reinvestment strategies for future development[173]. - The company is committed to enhancing its financial stability through prudent management of equity and reserves[171]. - The company has plans for market expansion and new product development, focusing on healthcare and technology sectors[143]. - The company is exploring potential mergers and acquisitions to strengthen its market presence and diversify its offerings[143]. - The company has outlined future performance guidance, aiming for a growth rate of approximately 10% in the upcoming fiscal year[143].

Financial Performance - Operating revenue increased by 33.97% to CNY 40,811,846.52 year-on-year[5] - Net profit attributable to shareholders rose by 8.34% to CNY 6,374,142.56[5] - Net profit after deducting non-recurring gains and losses surged by 47.64% to CNY 6,069,539.77[5] - Basic and diluted earnings per share decreased by 16.67% to CNY 0.05[7] - Total revenue for Q1 2021 was CNY 40,811,846.52, representing a 34.2% increase from CNY 30,462,390.90 in Q1 2020[27] - Net profit for Q1 2021 reached CNY 7,378,978.29, a 11.6% increase compared to CNY 6,614,680.73 in Q1 2020[28] - Operating profit for Q1 2021 was CNY 8,554,132.87, up 11.3% from CNY 7,687,190.27 in Q1 2020[28] - Comprehensive income for Q1 2021 totaled CNY 7,378,978.29, an increase from CNY 6,614,680.73 in Q1 2020[29] Cash Flow and Investments - Cash flow from operating activities showed a net outflow of CNY 51,838,262.91, worsening from a net outflow of CNY 44,991,571.69 in the previous year[5] - The company's cash flow from operating activities saw a 135.68% increase year-over-year, totaling ¥1,668,135.15, mainly due to higher interest income[17] - Cash inflow from operating activities in Q1 2021 was CNY 34,314,925.68, an increase of 25.5% compared to CNY 27,304,736.89 in Q1 2020[33] - Cash outflow from investing activities in Q1 2021 totaled CNY 64,800,526.88, significantly higher than CNY 17,178,468.19 in Q1 2020, indicating increased investment activity[34] - The company invested CNY 50,000,000.00 in Q1 2021, indicating a strategic focus on growth and expansion[37] Assets and Liabilities - Total assets decreased by 3.85% to CNY 958,984,906.41 compared to the end of the previous year[5] - Total assets amounted to CNY 997,404,072.75, with non-current assets totaling CNY 175,183,711.05[40] - Current liabilities decreased from ¥117,188,274.83 to ¥71,390,130.20, a reduction of about 39.1%[22] - Total liabilities reached CNY 119,788,274.83, with non-current liabilities at CNY 2,600,000.00[41] - The company reported a total current asset of ¥479,850,895.68, down from ¥512,239,855.07, a decrease of approximately 6.3%[25] Shareholder Information - The total number of shareholders reached 15,748 at the end of the reporting period[10] - The largest shareholder, Dai Jianwei, holds 42.00% of the shares[10] Research and Development - Research and development expenses surged by 51.18% year-over-year to ¥4,236,733.51, reflecting the company's increased investment in R&D projects[16] - R&D expenses increased to CNY 4,236,733.51 in Q1 2021, up 51.1% from CNY 2,802,363.50 in Q1 2020[27] Inventory and Costs - The cost of goods sold rose by 32.06% year-over-year to ¥19,154,037.80, in line with the revenue growth[15] - Inventory increased by 32.87% compared to the end of 2020, amounting to ¥32,718,943.17, driven by higher raw material purchases due to sales growth[13] - Total operating costs for Q1 2021 were CNY 31,247,677.80, up 30.2% from CNY 23,979,119.59 in Q1 2020[27] - Sales expenses rose by 34.07% year-over-year to ¥3,558,468.23, correlating with the increase in revenue[16] Other Financial Metrics - The weighted average return on equity decreased by 1.28 percentage points to 0.78%[5] - The company's tax payable decreased by 98.67% compared to the end of 2020, amounting to ¥374,080.21, due to the payment of fourth-quarter income tax[12] - The company's minority interest profit increased by 37.37% year-over-year, reaching ¥1,004,835.73, driven by higher profits from subsidiaries[18] - The company's cash and cash equivalents decreased to ¥438,938,640.02 from ¥559,879,717.59 at the end of 2020[21]

Financial Performance - The net profit attributable to the parent company's shareholders for 2020 was ¥95,739,268.21, with a total distributable profit of ¥303,280,521.11 as of December 31, 2020[4]. - The proposed cash dividend distribution is ¥2.15 per 10 shares (including tax), totaling ¥29,240,000.00 (including tax), which represents 30.54% of the net profit attributable to the parent company[4]. - The company's operating revenue for 2020 was CNY 286.81 million, a decrease of 4.47% compared to CNY 300.24 million in 2019[21]. - Net profit attributable to shareholders increased by 4.17% to CNY 95.74 million in 2020 from CNY 91.90 million in 2019[21]. - The company's total assets reached CNY 997.40 million at the end of 2020, representing a 106.76% increase from CNY 482.40 million at the end of 2019[22]. - Basic earnings per share for 2020 were CNY 0.94, up 4.44% from CNY 0.90 in 2019[23]. - The weighted average return on equity decreased to 29.01% in 2020 from 38.03% in 2019, a decline of 9.02 percentage points[23]. - The net cash flow from operating activities was CNY 71.78 million, down 5.60% from CNY 76.03 million in 2019[21]. - The company's net assets attributable to shareholders increased by 182.70% to CNY 813.15 million in 2020 from CNY 287.63 million in 2019[22]. - The company reported a net profit of CNY 36.70 million in Q4 2020, showing strong performance in the last quarter[25]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[3]. - The board of directors has thoroughly reviewed the timing and conditions for profit distribution, ensuring compliance with regulations[5]. - There are no non-operating fund occupations by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for external guarantees[8]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[6]. - The company is committed to maintaining the accuracy and completeness of the annual report, with all directors present at the board meeting[7]. Market and Industry Trends - The company focuses on intelligent drug management for the medical service and pharmaceutical distribution industries, aiming to enhance efficiency and service quality while reducing direct contact with hazardous drugs[30]. - The smart pharmacy project integrates hardware and software to automate drug storage, dispensing, and management, improving efficiency and reducing human error[32]. - The intelligent intravenous preparation center project utilizes various automated devices to ensure rapid and accurate drug preparation, minimizing direct contact with toxic chemicals[33]. - The intelligent drug and consumable management project employs IoT technology for secure storage and intelligent distribution of drugs and consumables[34]. - The global intelligent drug management equipment manufacturing industry has seen significant growth, with automation adoption rates in developed countries reaching approximately 30% by 2013[40]. - In the U.S., 97% of hospitals were equipped with automated dispensing devices by the end of 2014, indicating a strong trend towards automation in healthcare[40]. - In China, the demand for intelligent drug management systems has increased due to rising drug varieties and quantities, as well as higher service quality standards[41]. - The traditional drug management model is becoming inadequate, making intelligent drug management essential for hospitals to reduce operational costs and improve service quality[42]. Research and Development - The company has a well-established R&D system with nearly 20 years of experience in intelligent drug management, enhancing its technical innovation and new product development capabilities[50]. - The company has obtained a total of 111 authorized patents, including 6 invention patents and 67 software copyrights, enhancing its core competitiveness[60]. - The company is enhancing its R&D capabilities by collaborating with multiple technology firms to introduce advanced technologies into new product development[60]. - The total R&D expenditure for the period was ¥16,344,430.17, accounting for 5.70% of the operating revenue[78]. - The number of R&D personnel is 65, representing 19.06% of the total workforce[78]. Shareholder and Governance - The company has a history of consistent profit distribution, with previous years showing no cash dividends or stock dividends[116]. - The management team is committed to transparency and adherence to regulatory requirements regarding shareholding[121]. - The company reported a commitment from major shareholders to not transfer or delegate management of their shares for 36 months post-IPO[121]. - The controlling shareholder, Sun Dong, committed to not transferring or entrusting the management of shares held indirectly for 36 months post-listing[122]. - The company is focused on maintaining shareholder value through strict share transfer commitments[121]. - The company has established a priority right for the acquisition of any competing enterprises controlled by the shareholders if the company expands its business scope[145]. - The company has confirmed that there are no undisclosed related party transactions with its controlling shareholders[148]. - The company has retained Lixin Accounting Firm for its 2020 financial audit, with an audit fee of 700,000 RMB[151]. Social Responsibility - The company actively donated equipment to high-risk medical institutions during the pandemic, demonstrating its social responsibility[60]. - The company was awarded the "2020 Listed Company Social Responsibility Award" at the 10th China Public Welfare Festival[163]. - The company donated a self-service dispensing machine to Shenzhen Third People's Hospital to reduce patient wait times and infection risks[163]. - The company also donated an intelligent drug management cabinet to Jinan Central Hospital, aimed at reducing the workload of medical staff in isolation wards[163]. Risks and Challenges - The reliance on Willach for core components of the H series automated dispensing machine poses a significant risk to the company's operations[98]. - The COVID-19 pandemic has delayed the implementation of automated drug management projects, potentially impacting future performance[107]. - The company faces risks related to trade policy changes in Germany, which could affect the cost of imported raw materials[109]. - The production and sales of automatic dispensing machines are subject to restrictions based on joint venture agreements, which may limit market expansion[110]. - The accounts receivable balance as of 2020 was RMB 207.19 million, with a book value of RMB 234.15 million, indicating potential liquidity risks[104]. Future Strategies - The company plans to enhance R&D investment and talent development to maintain its leading position in the intelligent drug management sector[90]. - The market development strategy includes expanding into the retail pharmacy sector, which is currently experiencing lower automation levels compared to healthcare institutions[93]. - The company aims to improve its marketing and customer service network to penetrate deeper into the market, especially in less developed regions[92]. - The company is exploring opportunities for mergers and acquisitions to strengthen its competitive edge[120].